Researcher
Leo Heyndrickx
Projects
1 - 3 of 3
- Strengthening the capacity for research, teaching, policy advice, advocacy and networking of the partners in the field of human and animal health (South-Africa).From1 Jan 2018 → 31 Dec 2018
- To strengthen Institute of Tropical Medicine Pedro Kouri (IPK, Cuba) and National Institute of Hygiene, Epidemiology and Microbiology (INHEM, Cuba) towards accomplishment of their academic mission through capacity building and scientific co-operation.From1 Jan 2018 → 31 Dec 2018
- To strengthen the R&D capacities of the Institute of Tropical Medicine Alexander von Humboldt (Peru) to deliver strategies and/or tools for diagnosis, surveillance and control of infectious diseases.From1 Nov 2017 → 31 Dec 2021
Publications
1 - 10 of 130
- Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-Centre, randomized controlled pilot trial(2023)
Authors: Nicole Berens-Riha, Petra Andries, Annelies Aerssens, Quentin Ledure, Yolien Vanderbeken, L Heyndrickx, Els Genbrugge, Achilleas Tsoumanis, Y Van Herrewege, Kevin K Ariën, et al.
- Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults(2023)
Authors: Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Daphnée Georges, Sarah Houben, Véronique Olislagers, Alexandra Waegemans, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, et al.
Pages: 2829-2836 - Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients(2023)
Authors: Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, Maria E. Goossens, Isabelle Desombere, et al.
Pages: 649-658 - Validation of a reporter cell line for flavivirus inhibition assays(2023)
Authors: Tatiana M T Rezende, Gabriella Macera, L Heyndrickx, J Michiels, Sandra Coppens, Hendrik Jan Thibaut, Kai Dallmeier, Marjan Van Esbroeck, Johan Neyts, Kevin K Ariën, et al.
- SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations(2023)
Authors: Andrew P Hederman, Harini Natarajan, L Heyndrickx, Kevin K Ariën, Joshua A Wiener, Peter F Wright, Evan M. Bloch, Aaron A. R. Tobian, Andrew D Redd, Joel N Blankson, et al.
- Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant(2022)
Authors: Kevin K Ariën, L Heyndrickx, J Michiels, K Vereecken, Kurt Van Lent, Sandra Coppens, B Willems, Pieter Pannus, Geert A Martens, Marjan Van Esbroeck, et al.
- Chikungunya virus' high genomic plasticity enables rapid adaptation to restrictive A549 cells(2022)
Authors: Lien De Caluwe, L Heyndrickx, Sandra Coppens, K Vereecken, Miguel E Quiñones-Mateu, Andres Merits, Kevin K Ariën, Koen Bartholomeeusen
- Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial(2022)
Authors: Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven, L Heyndrickx, J Michiels, B Willems, Stéphane De Craeye, Antoine Francotte, et al.
Pages: e0001308 - A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell mediated immunity(2022)
Authors: Sean McCafferty, Akm Ashiqul Haque, Aster Vandierendonck, Brian Weidensee, Magalie Plovyt, Magdalena Stuchlíková, Nathalie François, Sophie Valembois, L Heyndrickx, J Michiels, et al.
Pages: 2968-2983 - A high-throughput yellow fever neutralization assay(2022)
Authors: Madina Rasulova, Thomas Vercruysse, Jasmine Paulissen, Catherina Coun, Vanessa Suin, L Heyndrickx, Ji Ma, Katrien Geerts, Jolien Timmermans, Niraj Mishra, et al.